

# A Cross-sectional Study to Evaluate Diabetes Management, Control and Complications in Patients with type 2 Diabetes in Bangladesh

Latif ZA<sup>a</sup>, Ashrafuzzaman SM<sup>a</sup>, Amin MF<sup>a</sup>, Gadekar AV<sup>b</sup>, Sobhan MJ<sup>c</sup>, Haider T<sup>c</sup>

## Abstract

**Background:** Management of type 2 diabetes is not uniform. The aim of the study was to assess diabetes care delivery and status of long-term diabetes related complications.

**Methods:** DiabCare is an observational, non-interventional, cross-sectional study of hospital-based outpatient type 2 diabetes care.

**Results:** A total of 2092 patients participated in the study: mean age 51.3±11.0 years, and duration of diabetes 7.6±5.4 years. The patients were almost equal in both genders (male: 49.8% vs. female: 50.2%) and the largest homogenous ethnic group was Bangladeshi (99.6%). The percentage of patients with HbA1c < 7.0% (< 53 mmol/mol) was 22.5% and mean HbA1c was 8.8±2.2%. The proportion of patients using insulin was 58.0% (n=1214) at a total daily dose of 34.4±14.7 IU. The most common diabetes related complications were: Peripheral neuropathy (39.0%) and eye complications (21.7%). Duration of diabetes was associated with higher odds of CV complications, diabetic nephropathy and eye complications [adjusted OR 1.03, p=0.007; 1.05, p<0.001 and 1.05, p<0.001 respectively]. Age also has emerged as a significant predictor for these complications. More than half of patients (56.1%) indicated their concerns about hypoglycaemia. A large proportion of patients were non-adherent to clinical recommendations.

**Conclusions:** Poor glycaemic and metabolic control over a long period of time contributes to chronic diabetic complications. This underpins the need to further optimise the control strategies and maintain quality diabetes management standards in Bangladesh and also improving awareness among health professionals with intensive education programs for diabetes subjects is also recommended.

**Key words:** Diabetes mellitus, hospital care, prevention, diabetes complications, treatment adherence, hypoglycaemia

(BIRDEM Med J 2017; 7(1): 17-27)

## Introduction

Estimates in 2015 indicate that approximately 8.5%, equivalent to 78.3 million, of the adult population living in South East Asia (SEA) region suffer from type 2 diabetes mellitus

## Author Informations

- Dr. Zafar Ahmed Latif, SM Ashrafuzzaman, Mohammod Feroz Amin, BIRDEM Hospital, Dhaka, Bangladesh
- Dr. Arvind Vilas Gadekar, Novo Nordisk Pharma Operations (BASEA), Kuala Lumpur, Malaysia
- Dr. Md. Javed Sobhan, Tanvir Haider, Novo Nordisk, Bangladesh

**Address of Correspondence:** Dr. Zafar Ahmed Latif, Director, BIRDEM Academy, E-mail: zaforalatif2011@yahoo.com

**Received:** October 18, 2015      **Accepted:** November 30, 2016

(T2DM). SEA region also witnessed 24.2% of all live births affected by high blood glucose during pregnancy. The projected increase of DM population in SEA, to 140.2 million by 2040, is a major threat to public health resources.<sup>1,2</sup> Urbanisation, change in lifestyle and high life expectancy are cited as reasons for the increasing prevalence of T2DM.<sup>3</sup>

Bangladesh rank second in T2DM prevalence among SEA countries. Saquib et al (2012) in a meta-analysis of studies conducted between 1995 and 2010, showed continuous increase in pooled T2DM prevalence at the rate of 3.8% (1995-2000), 5.3% (2001-2005), and 9.0% (2006-2010). (4) Currently, 7.1 million people are

affected with T2DM in Bangladesh, turning it into 10<sup>th</sup> highest T2DM burden country in the world.<sup>1</sup> IDF atlas (2015) projects 13.6 million adults in Bangladesh to suffer from T2DM by 2040.<sup>1</sup>

This staggering toll of T2DM and its complications has also increased the total disability adjusted life years (DALYs) by nearly 70% between 1990 and 2010 in Bangladesh, which is much higher than DALYs attributed to cardiovascular disease and cancer (25%).<sup>5</sup> This has led to high economic cost, productivity losses and intangible cost (psychological pain to the family and loved ones), past human suffering.<sup>2</sup>

Strategies to improve diabetes care, thereby mitigating diabetes-related complications are urgently needed. Early screening in high risk groups and proper management is recommended to avoid early complications. A regular audit of diabetes management is an essential step towards the prevention and control.<sup>6</sup> Periodic evaluations help in assessing the usefulness of measures taken and also depict seriousness of the policies towards global commitment in accordance with the World Health Organization's action plan, en route to achieving long and healthy life.<sup>7</sup>

The DiabCare, a series of cross-sectional observational studies, was started in Europe in 1990s with the collaboration of Novo Nordisk. The primary goal of these studies was to appraise the performance of diabetes care system through participation of large number of patients and clinicians over time. This survey, was not limited to the evaluation of diabetes management, but has also explored the psychological aspect of participating patients.<sup>8</sup> DiabCare Asia was initiated in 1997 in 6 countries including Bangladesh.<sup>9</sup> (9) DiabCare Bangladesh 1998 and 2008 have informed healthcare policy and influenced diabetes management programmes in the country.<sup>10,11</sup> Consistent with previous studies, DiabCare Bangladesh 2012 was performed to describe diabetes management, control and complications. It also evaluated the associated primary and secondary preventive efforts and treatment adherence in patients with T2DM living in Bangladesh.

## Methods

### *Study design and setting*

An observational, non-interventional, cross-sectional design was used for this study (Universal trial number (UTN): U1111-1137-2729). The study was conducted

between June 2013 to September 2013 at 80 secondary care and 20 tertiary care hospitals in Bangladesh. All aspects of the study were conducted in accordance with the Declaration of Helsinki<sup>12</sup> and the Guidelines for Good Pharmacoepidemiology Practice (GPP),<sup>13</sup> supervised by study investigators and their deputies. Due to the observational nature of this study, there were no study-specific visits or investigational products and patients were treated according to routine clinical practice at the discretion of the attending physician.

### *Study participants*

Patients routinely visiting the centre during the study period were screened for eligibility. Before any study-related activity, investigators or their deputies gave eligible patients comprehensible oral and written information about the study and obtained informed consent. Adults over the age of 18 years with T2DM on non-pharmacological or pharmacological treatment who had been at the centre for at least one year and had visited the centre within the last 3-6 months were included, if they provided informed consent. Patients who had previously participated in the study, had suspected or confirmed pregnancy or were unable to comply with protocol requirements were excluded from the study. Patients were permitted to withdraw from the study at will at any time. Recruitment and enrolment continued until the target number of patients was reached.

### *Study endpoints*

The primary endpoint of the study was defined as the proportion of patients with glycosylated haemoglobin (HbA1c) less than 7% (53 mmol/mol) at study entry.<sup>14</sup> (14) This was chosen as the primary endpoint due to the validity of HbA1c as an indicator of diabetes care. The secondary endpoints were: duration of diabetes, duration and type of treatment, other measures of glycaemic control (fasting plasma glucose (FPG) and post-prandial glucose (PPG)), lipid control (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and fasting triglycerides), presence of known risk factors or diabetes-related complications (dyslipidaemia, hypertension, cardiovascular complications, peripheral vascular disease, diabetic nephropathy, and diabetic eye complications), hypoglycaemia, and treatment adherence. Potential predictor variables including age, gender, body mass index (BMI), diabetes duration,

hypertension, insulin therapy, use of multiple oral anti-diabetic agents (OADs), HbA1c, FPG and performance of self-measurement of blood glucose (SMBG) were analysed for their relationship with various complications.

#### **Data sources and measurement**

Relevant data were collected from patients' medical records and recorded in case report forms (CRFs) designed for this study. Data collected included demography, medical history, complications, eye and foot examinations, diabetes management and most recent laboratory investigations performed within the past one year. Blood samples were collected for HbA1c measurement. The decision of lab selection, supervision and quality assurance of the centralized measurements were performed by Bangladesh institute of research and rehabilitation in diabetes, endocrine and metabolic disorders (BIRDEM). The blood samples were stored between 2°C to 8°C. HbA1c was measured through venous/capillary blood as per NGSP guidelines (National Glycosylated Standardisation Programme) using BioRad HPLC (High Performance Liquid Chromatography) D 10 or Variant 2 method. Blood samples were stored only for retest purpose and promptly disposed after the completion of the HbA1c analysis. In addition, patients were asked to complete a treatment adherence questionnaire and a hypoglycaemia questionnaire which were administered by investigators or their deputies. The treatment adherence questionnaire included patient adherence to diet, exercise, taking medication as prescribed, performance of SMBG testing and keeping appointments with healthcare professionals. The hypoglycaemia questionnaire assessed symptoms of hypoglycaemia categorised as mild (sweating, dizziness, trembling, tingling in the hands, feet or lips, blurred vision, difficulty in concentrating, palpitations and occasional headache); moderate (odd behaviour such as rudeness or laughter, bad temper or moodiness, aggressive behaviour, confusion); severe (loss of consciousness or needing help from another person); or nocturnal (any symptoms between bedtime and breakfast). The hypoglycaemia questionnaire also assessed patient responses to hypoglycaemia including SMBG testing, snacking, skipping or changing medication doses, visiting hospital and patient concern.

Patient information collected for this study was kept confidential and measures such as encryption were enforced to protect patient identity. Sensitive patient data were kept with investigators according to local regulations regarding personal data protection.

#### **Study size**

The study aimed to enrol a total of 2092 patients from Bangladesh. The sample size was based on published data and consultation with local external experts. The prevalence of cardiovascular disease (CVD) was used as a basis for the study size target because available literature suggests that this is the least prevalent of all diabetic complications and its use confers the maximum possible representativeness to the sample size estimate. Assuming a CVD prevalence of 2%, a sample of 2092 patients conforms to a 5% level of significance and 30% margin of error.

#### **Statistical analysis**

The full analysis set (FAS) included all patients with at least one data point. Missing data was not replaced. The data analysis was performed using SAS, Version [9.2]. Continuous variables were summarised using descriptive statistics: mean  $\pm$  standard deviation (SD), median (range), and number missing. Categorical variables were presented as number and percentages (%). Percentages were based on all patients in the respective patient set regardless of whether they had non-missing values or not.

The influence of potential predictor variables on outcome variables (any diabetes complications) were evaluated by analysis of covariance (ANCOVA) for continuous variables, and by logistic regression for categorical variables. The following predictor variables were assessed separately in the univariate analyses: age, sex, BMI, duration of diabetes, hypertension, insulin therapy, use of multiple OADs, HbA1c, FPG and SMBG (testing done or not done). In a second step, all risk factors were included in the multivariate analysis and a backward stepwise regression method was used to identify significant predictors. Three of the variables - age, gender and duration of diabetes were retained in each final model to allow for adjustment of their effects. For continuous predictors, odds ratio estimates for a change in 1 unit were presented with corresponding 95% confidence intervals and two-sided p-values. For categorical predictors, odds ratio estimates between categories were presented with corresponding 95% confidence intervals and two-sided p-values.

#### **Results**

##### **Patient characteristics and demographics**

2092 participants with mean age of 51.3 $\pm$ 11.0 years, 49.8% male and 50.2% female, were enrolled in this study. The largest ethnic group was Bangladeshi (n=2084, 99.6%). Majority of patients belonged to lower

middle income group (n=1156, 55.3%) and had family history of DM (n=1286, 61.5%). The median duration of T2DM was 6 (min 1: max 37) years. Approximately one third, (n=766, 36.6%) of patients led a sedentary lifestyle and mean waist circumference was 87.2±9.5 cm (Table I).

**Table I. Demographic and General Patient Characteristics**

Variables	N=2092
Age (years)	
Mean (SD)	51.3 (11.0)
Median	50.0
(Min, Max)	(18.0, 95.0)
Male gender n, (%)	1041 (49.8)
Female gender n, (%)	1051 (50.2)
Duration of diabetes (years)	7.6 (5.4)
Mean (SD)	6.0
Median	(1.0, 37.0)
(Min, Max)	
Waist circumference (cm)	
Mean (SD)	87.2 (9.5)
Median	86.0
(Min-Max)	(60.0, 130.0)
Ethnic groups (n, %)	
Bangladeshi	2084 (99.6)
Others	8 (0.4)
Health Expenses (n, %)	
Government/Community	23 (1.1)
Self	2051 (98.0)
Insurance	75 (3.6)
Educational status (n, %)	
LCTRW#	299 (14.3)
5 years	439 (21.0)
10 years	724 (34.6)
Graduate	466 (22.3)
Postgraduate	164 (7.8)
Economic status, n (%)	
Low Income Group	428 (20.5)
Lower Middle Income Group	1156 (55.3)
Upper Middle Income Group	454 (21.7)
High Income Group	54 (2.6)
Risk Factors (n, %)	
Family History	1286 (61.5)
Currently smoking	237 (11.3)
Sedentary	766 (36.6)

All continuous data are presented as mean ± standard deviation and median (range). Percentage (%) values calculated from total non-missing. #LCTRW: Limited Capacity to Read and Write

### Glycaemic control

The mean HbA1c (%) of the studied population was 8.8±2.2. The American Diabetes Association's (15) recommended HbA1c target of <7% was met by approximately one fifth (22.5%) of patients whereas 27.7% patients had greater than 10.0% HbA1c. 41% patients were evaluated for HbA1c over the past year and the mean testing frequency was 2.1±2.1 times per year. The median FPG and PPG of this cohort was 8.6 and 12.0 mmol/L respectively. Owing to high inter-subject variability, mean FPG and PPG were skewed. The distribution of patients as per their HbA1c, FPG and PPG is presented in Table II.

**Table II. Glycaemic control status**

Glycaemic profile	N= 2092
HbA1c (%)	
Mean (SD)	8.8 (2.2)
Median	8.4
(Min, Max)	(4.7, 14.7)
HbA1c quantile (n, %)	
< 7.0% (<53 mmol/mol)	471 (22.5)
7.0% to < 8.0% (53 mmol/mol to <64 mmol/mol)	406 (19.4)
8.0% to < 9.0% (64 mmol/mol to 75 mmol/mol)	350 (16.7)
9.0% to < 10.0% (75 mmol/mol to <86 mmol/mol)	285 (13.6)
≥10.0% (86 mmol/mol)	580 (27.7)
Plasma Glucose	
FPG (mmol/L)	
Mean (SD)	16.0 (35.0)
Median	8.6
(Min, Max)	(3.9, 360.0)
Missing (n)	56
PPG (mmol/L)	
Mean (SD)	22.3 (48.3)
Median	12.0
(Min, Max)	(7.8, 360.0)
Missing (n)	11

All continuous data are presented as mean ± standard deviation and median (range). Percentage (%) values calculated from total non-missing.

### Lipid profile and blood pressure

The proportion of patients with dyslipidaemia was 56%, however, only 38.8% were on dyslipidaemia medication. The mean total cholesterol, high density lipoprotein (HDL), low density lipoprotein (LDL) and triglycerides were 5.2±1.3, 1.1±0.3, 3.3±1.1 and 2.3±1.0 mmol/L respectively. Statins (85.1%) and fibrates (18.9%) were two most commonly prescribed dyslipidaemia drugs (Table III).

**Table III.** Control status of blood pressure and lipids

Blood pressure	
Systolic (mmHg)	
Mean (SD)	124.4 (12.0)
Median	120.0
(Min, Max)	(80.0, 200.0)
Diastolic (mmHg)	
Mean (SD)	80.0 (6.9)
Median	80.0
(Min, Max)	(40.0, 110.0)
Hypertension <sup>a</sup> (n, %)	1180 (56.4)
Hypertensive medication (n, %)	1062 (50.8)
Anti-hypertensive medication (n, %)	
ACE inhibitor	328 (30.9)
ARB	377 (35.5)
Alpha Blocker	43 (4.0)
Alpha-2-Agonist	50 (4.7)
Beta-blocker	304 (28.6)
Ca <sup>2+</sup> Channel Antagonist	267 (25.1)
Diuretics	186 (17.5)
Other	45 (4.2)
Lipids	
Total Cholesterol (mmol/L)	
Mean (SD)	5.2 (1.3)
Median	5.2
Min, Max	2.6, 10.3
Missing (n)	957
HDL Cholesterol (mmol/L)	
Mean (SD)	1.1 (0.3)
Median	1.0
(Min, Max)	(0.1, 3.4)
Missing (n)	957
LDL Cholesterol (mmol/L)	
Mean (SD)	3.3 (1.1)
Median	3.2
(Min, Max)	(1.3, 7.1)
Missing (n)	957
Fasting Triglycerides (mmol/L)	
Mean (SD)	2.3 (1.0)
Median	2.1
(Min, Max)	(1.1, 6.8)
Missing (n)	957
Dyslipidaemia <sup>b</sup>	1171 (56.0)
Missing (n)	27
Dyslipidaemia medication (n, %)	
Dyslipidaemia medication (n, %)	811 (38.8)
Statin	690 (85.1)
Fibrate	153 (18.9)
Niacin	1 (0.1)
Ezetimibe	8 (1.0)
Other	11 (1.4)

All continuous data are presented as mean  $\pm$  standard deviation and median (range). Percentage (%) values calculated from total non-missing.

<sup>a</sup> Hypertension was defined as patients currently taking medication for hypertension, or systolic blood pressure (SBP)  $\geq 140$  mmHg, or diastolic blood pressure (DBP)  $\geq 90$  mmHg.

<sup>b</sup> Dyslipidaemia was defined as patients currently taking medication for dyslipidaemia or presented with low density lipoprotein (LDL) cholesterol  $>2.6$  mmol/L, or high density lipoprotein (HDL) cholesterol  $<1.0$  mmol/L in males and  $<1.3$  mmol/L in females, or triglycerides  $>1.7$  mmol/L.

56.4% patients were hypertensive with only 50.8% taking anti-hypertensive medication. The mean systolic and diastolic blood pressure was  $124.4 \pm 12.0$  and  $80.0 \pm 6.9$  mmHg respectively. The most frequently used anti-hypertensive medications were angiotensin-II receptor blockers (ARBs) (35.5%) and angiotensin-converting enzyme (ACE) inhibitors (30.9%) (Table III). Duration of diabetes, higher BMI and higher HbA1c were predictive for both hypertension and dyslipidemia.

**Table IV.** Diabetes-related complications

Eye complications (n, %)	454 (21.7)
Screened for eye disease within the last two years	861 (41.2)
Background diabetic retinopathy non-proliferative	183 (8.7)
History of photocoagulation	30 (1.4)
Proliferative diabetic retinopathy	72 (3.4)
Severe vision loss	101 (4.8)
Macular oedema	20 (1.0)
Cataract	189 (9.0)
Cardiovascular complications (n, %)	352 (16.8)
Myocardial infarction	113 (5.4)
Angina	170 (8.1)
Peripheral vascular disease	84 (4.0)
Stroke	50 (2.4)
Congestive Heart Failure	22 (1.1)
Atrial fibrillation	2 (0.1)
Left Ventricular Hypertrophy	24 (1.1)
History of a revascularisation procedure (e.g. CABG)	19 (0.9)
Renal complications (n, %)	280 (13.4)
Screened for renal disease within the last two years	723 (34.6)
Microalbuminuria	210 (10.0)
Gross proteinuria	83 (4.0)
End-stage renal disease	12 (0.6)
Dialysis	4 (0.2)
Foot complications (n, %)	239 (11.4)
Active ulcer	114 (5.4)
Healed ulcer	118 (5.6)
History of amputation	56 (2.7)
Erectile dysfunction (n, %)	164 (15.8)
Peripheral neuropathy (n, %)	815 (39.0)

All continuous data are presented as mean  $\pm$  standard deviation and median (range). Percentage (%) values calculated from total non-missing.

**Table-V.** Results of multivariate analyses to identify independent predictors of selected diabetes complications

Independent variables	Adjusted odds ratio (95% CI)p-value			
	Cardiovascular Complications*	Peripheral Vascular Disease	Diabetes Nephropathy <sup>†</sup>	Eye Complications <sup>‡</sup>
Age [in years]	1.04 (1.03, 1.05)<0.001	1.01 (0.99, 1.03)0.406	1.02 (1.01, 1.04)<0.001	1.05 (1.04, 1.06)<0.001
Gender [Male vs Female]	1.37 (1.08, 1.73)0.010	1.64 (1.06, 2.53)0.027	0.83 (0.64, 1.06)0.139	0.91 (0.73, 1.13)0.405
Duration of diabetes [in years]	1.03 (1.01, 1.05)0.007	1.01 (0.97, 1.05) 0.740	1.05 (1.02, 1.07)<0.001	1.05 (1.03, 1.07)<0.001
HbA1c value [%]	1.09 (1.03, 1.15)0.003	-	-	1.07 (1.02, 1.13)0.007
FPG value [mmol/L]	0.99 (0.99, 1.00)0.012	-	0.99 (0.99, 1.00)0.010	0.99 (0.99, 1.00)0.004
Hypertension <sup>§</sup>	2.66 (2.04, 3.48)<0.001	-	2.02 (1.53, 2.67)<0.001	-

\*Cardiovascular complications: myocardial infarction, peripheral vascular disease, congestive heart failure, left ventricular hypertrophy, angina, stroke/transient ischaemic attack, atrial fibrillation or history of revascularisation procedure.

<sup>†</sup>Diabetic nephropathy: Microalbuminuria, gross proteinuria, end-stage renal disease or dialysis.

<sup>‡</sup>Eye complications: Non-proliferative retinopathy, proliferative diabetic retinopathy, macular oedema, history of photocoagulation, severe vision loss or cataract.

<sup>§</sup>Hypertension: SBP  $\geq$ 140 or DBP  $\geq$ 90 mmHg, or on medications for hypertension

||Multiple OADs: At least 2 oral medications (except herbal medicine).

For continuous variables, the results are for per unit increase in variable.

### Diabetes-related complications

The most commonly seen diabetes related complications were peripheral neuropathy (39.0%) and eye complications (21.7%). The proportion of patients with cardiovascular (CV), renal, foot complications, and erectile dysfunction were 16.8%, 13.4%, 11.4% and 15.8% respectively. Approximately 34.6% had been screened for renal complications in past two years. The most commonly encountered renal complication was microalbuminuria (10.0%) followed by gross proteinuria (4.0%). Cataract (9.0%) and non-proliferative diabetic retinopathy (8.7%) were the most common eye complications. Angina was the most frequently reported CV complication and 2.7% of T2DM patients had amputation. (Table-IV)

Duration of T2DM and age were strongly correlated with selected diabetes complications including cardiovascular (Adjusted OR=1.03 p=0.007 & 1.04 p<0.001), renal (Adjusted OR=1.05 p<0.001 & 1.02 p<0.001) and eye complications (Adjusted OR=1.05 p<0.001 & 1.05 p<0.001 respectively]. Hypertension

was predictive of CV complications and diabetic nephropathy (p <0.001 and p <0.001, respectively). Higher HbA1c showed greater odds of developing CV and eye complications (Table-V).

### Diabetes management

Majority of patients (92.3%) were receiving treatment for diabetes. 58.0% patients were on insulin treatment (either alone or combination with OAD). The most commonly prescribed OADs were metformin (81.8%) and sulphonylureas (52.6%). The mean duration of OAD treatment and insulin therapy was 5.9 $\pm$ 4.4 and 4.4 $\pm$ 4.4 years respectively.

Premix twice daily (83.4%) was the most commonly prescribed insulin regimen. Basal+OAD and basal-bolus regimen were used by 2.4% and 9.9% patients respectively. The mean number of injections per day and mean total daily insulin dose was 2.2 $\pm$ 0.7 and 34.4 $\pm$ 14.7 IU respectively. In 80.6% patients, insulin was administered through vial or syringe, while 19.4% patients used Pen devices. The pharmacological treatments are summarised in Table VI.

**Table VI.** Pharmacological diabetes treatments

Duration of diabetes [years]	
n	2092
Mean (SD)	7.6 (5.4)
Median	6.0
(Min, Max)	(1.0, 37.0)
Duration of treatment [years]	2092
Mean (SD)	7.1 (5.2)
Median	6.0
(Min, Max)	(1.0, 36.0)
Duration of OAD treatment [years]	1943
Mean (SD)	5.9 (4.4)
Median	5.0
(Min, Max)	(0.0, 36.0)
Missing	149
Duration of insulin treatment [years]	
n	1235
Mean (SD)	4.4 (4.4)
Median	3.0
(Min, Max)	(0.0, 33.0)
Missing	857
Current antidiabetic (oral/non-insulin injectables) therapy, n (%)	
Yes	1930 (92.3)
No	162 (7.7)
Current insulin therapy, n (%)	
Yes	1214 (58.0)
No	878 (42.0)
Diabetes Treatment, OAD (n, %)	
Metformin	1579 (81.8)
Sulphonylurea	1015 (52.6)
Thiazolidinedione	206 (10.7)
Glucosidase Inhibitor	68 (3.5)
Glinide	35 (1.8)
DPP4 Inhibitor	286 (14.8)
GLP-1 Analogue	16 (0.8)
Herbal/Traditional Medicine	15 (0.8)
Insulin	1214 (58.0)
Insulin Delivery (n, %)	
Pen Device	236 (19.4)
Vial/Syringe	978 (80.6)
Insulin Regimens (n, %)	
Basal + OAD	29 (2.4)
Premix OD	19 (1.6)
Premix BD	1013 (83.4)
Premix TID	32 (2.6)

Basal-Bolus	120 (9.9)
Total Daily Insulin Dose (IU/d)	
All Regimens	
Mean (SD)	34.4 (14.7)
Median	32.0
(Min, Max)	(6.0, 108.0)

All continuous data are presented as mean  $\pm$  standard deviation and median (range). Percentage (%) values calculated from total non-missing.

### **Treatment adherence**

A large proportion of patients were non-adherent to clinical recommendations regarding diet (52.3%), exercise (65.4%) and self-testing (74.5%). Around one third (32.2%) of patients were non-compliant to their prescribed medications and even substantial proportion of patients (51.0%) did not completely adhere to scheduled appointments with healthcare professionals.

### **Hypoglycaemia**

The incidences of mild, moderate, severe and nocturnal hypoglycaemia reported within the past three months were 33.5%, 9.3%, 3.0% and 8.8%, respectively (Table VII). More than half of patients (54.7%) indicated their concerns about hypoglycaemia. Among patients who experienced hypoglycaemia, 80.3% either never checked their blood glucose or checked occasionally. Small proportion of patients (9.3%) measured their blood glucose frequently for a few days following an episode. Most of the patients (82.7%) never visited a hospital, or visited on rare instances after hypoglycaemic episodes. 45.3% had performed SMBG over the past year, at a median frequency of 2.0 (1.0-30.0) times in the past month. In addition, 70.2% patients started snacking between meals and even a substantial proportion of patients (31.6%) skipped or reduced their diabetes medications because of hypoglycaemia.

### **Quality of life**

Though patients' responses to the EQ-5D questionnaire were collected, the use of a modified version of the EQ-5D form violated the user agreement with the instrument owner (EuroQol group) and rendered the data unsuitable for analysis.

**Table VIII.** Hypoglycaemia questionnaire

Hypoglycaemia symptoms in the last 3 months		
Mild 'hypo' - Sweating, dizziness, trembling, tingling in the hands, feet or lips, hunger, blurred vision, difficulty in concentrating, palpitations and occasional headache.	N (%)	701 (33.5)
	Number of episodes	
	Mean (SD)	1.9 (1.3)
Moderate 'hypo' - Odd behaviour such as rudeness or laughter (appearing drunk when you are not), bad temper or moodiness, aggressive behaviour, confusion.	Median	2.0
	(Min,Max)	(1.0, 10.0)
	N (%)	195 (9.3)
Severe 'hypo' - Unconsciousness or help from someone else.	Number of episodes	
	Mean (SD)	1.6 (0.8)
	Median	1.0
Nocturnal 'hypo' - Symptoms between bedtime and breakfast.	(Min,Max)	(1.0, 5.0)
	N (%)	63 (3.0)
	Number of episodes	
	Mean (SD)	1.4 (0.8)
	Median	1.0
	(Min,Max)	(1.0, 6.0)
	N (%)	185 (8.8)
	Number of episodes	
	Mean (SD)	1.6 (1.2)
	Median	1.0
	(Min,Max)	(1.0, 12.0)

All continuous data are presented as mean  $\pm$  standard deviation and median (range).

### Discussion

DiabCare Bangladesh 2012 more competently describes diabetes care currently being delivered, the challenges associated with improving care and the future role of diabetes prevention. It has enrolled relatively higher patients (2092) as compared to previous DiabCare studies.<sup>10</sup> The mean age of the patients (51.3 years) is consistent with previous DiabCare and other studies conducted in Bangladesh.<sup>10,16</sup> The patients in this study had relatively shorter disease duration (6 years) as compared to DiabCare 2008 (7.9 years). Greater proportion of patients with family history of diabetes (61.5% vs. 52.8%) and smoking habits (11.3% vs. 8.2%) has been observed as compared to DiabCare 2008 study. The increasing incidence of risks emphasise the need of primary prevention programs for T2DM management in Bangladesh.

Using multiple diagnostic criteria, as assessed by centralized HbA1c, FPG and PPG measurements, DiabCare Bangladesh 2012 showed unsatisfactory glycaemic control in majority of patients surveyed. The mean HbA1c of 8.4% is similar to two previous DiabCare studies of 2008 (8.6%) and 1998 (7.9%).<sup>10,11</sup> Islam et al (2015) also recently demonstrated mean HbA1c of 8.3% in 515 T2DM patients.<sup>17</sup> The proportion of patients with poor glycaemic control (HbA1c  $\geq$ 7.0%) within this cohort is comparable (77.5%) to the DiabCare 2008 (76.9%), but greater than that of 1998 study (63.3%).<sup>10,11</sup> The median FPG is also consistent with DiabCare 2008 study (8.4 $\pm$ 2.7 mmol/L).<sup>10</sup> Sultana et al found mean FPG levels of 8.9 $\pm$ 3.6 mmol/L in a prospective study from a tertiary care setting (n=140) in Bangladesh.<sup>16</sup>



Suboptimal glycaemic control is probably attributed to low frequency of HbA1c testing, life style modification and treatment compliance.<sup>14</sup> Approximately 59% of patients have not evaluated HbA1c in the past year. Patient responses to the hypoglycaemia questionnaire also showed their non seriousness in monitoring blood glucose. Further, high proportion of patients did not adhere to treatment-related advice and a substantial proportion did not adhere to their prescribed regimens. Over one third of patients accustomed to a sedentary lifestyle. Rising life expectancies coupled with ‘unhealthy’ ageing and sedentary lifestyle present a new set of challenges in developing countries. Hence, policies focusing on prevention should emphasise the need to promote frequent HbA1c testing, improve patient adherence and lifestyle modification.

Microvascular and macrovascular complications in the current and 2008 DiabCare demonstrated neuropathy symptoms (39.0% vs 31.7%), microalbuminuria (10.0% vs 15.7%), cataract (9.0% vs 12.9%), myocardial infarction (5.4 vs 5.2%), active ulcer/gangrene (5.4% vs 2.9%), cerebral stroke (2.4% vs 2.2%), and leg amputation (2.7% vs 1.2%). DiabCare Bangladesh 2012 has observed higher incidences of peripheral neuropathy, active ulcer/gangrene and leg amputation.<sup>10</sup> Sultana et al (2013) reported 21% cataract, 14% nephropathy, 35% neurological problems and 6% kidney problems in T2DM patients in Bangladesh.<sup>16</sup> Duration of diabetes has emerged as a significant risk for both micro- and macrovascular complications, which is similar to other reported studies.<sup>18,19</sup> Kibriya et al. (1998) also demonstrated the correlation of longer duration of diabetes with neuropathy, nephropathy and retinopathy.<sup>11</sup>

Proportion of patients using OADs has increased (92.3%) in the current DiabCare compared to that of 2008 (89.1%) and 1998 (65.9%) respectively.<sup>10,11</sup> Biguanides (81.8%) followed by sulphonylureas (52.6%) are the most commonly used OADs in the current DiabCare, whereas the trend of sulphonylurea (55.8%) prescription was more than biguanides (54.2%) in 2008. Recently Ahmed et al (2016) has also revealed metformin as the single most prescribed

OADs. Increasing prescription of metformin in patients with T2DM in Bangladesh is attributed to its negligible risk of hypoglycaemia and potential cardiovascular and metabolic benefit as compared to sulphonylureas.<sup>21</sup>

58% of patients are insulin users in the current study which is almost three-fold as compared to DiabCare Bangladesh 1998 study (21.8%) and higher than DiabCare 2008 (42.7%).<sup>10,11</sup> The frequency of insulin pen user has increased from 13.5% in 2008 to 19.4% patients in the current study. Premix twice daily (83.4%) has remained the most commonly prescribed insulin regimen (DiabCare 2008; 82.8%).<sup>10</sup> Increased frequency of insulin users reflects more aggressive management strategy adopted in Bangladesh in T2DM patients as recommended by previous DiabCare studies. The United Kingdom Prospective Diabetes Studies (UKPDS) has also showed that the control of glycaemia was maintained in 50% of T2DM patients, who had been getting insulin treatment for over 6 years.<sup>22</sup> However still a large proportion of patients have not met target HbA1c or blood glucose levels in the current DiabCare.

Higher proportion of T2DM patients had hypertension (56.4%) as compared to 2008 and 1998 study (47% vs. 35.8%). However, proportion of dyslipidemia is consistent with DiabCare 1998 and 2008 Bangladesh studies.<sup>10,11</sup> Results also showed older age, HbA1c, and FPG to be associated with higher odds of dyslipidaemia and hypertension. Efforts to control blood glucose levels as well as cardiovascular risk factors such as lipids or hypertension is imperative for successful management of T2DM.

The findings of this study need to be interpreted in light of the study limitations. Firstly, due to the cross-sectional observational nature of the study, it is not possible to completely exclude the effect of selection bias and also to draw conclusions on the impact of treatment. Secondly, as all centres offered specialised diabetes care services, patients attending these centres, who were eligible for enrolment in the study, may not be representative of the country as a whole. Thirdly, data on treatment adherence and hypoglycaemia were self-reported, and the estimates may have been subject to recall bias. Further, due to the retrospective

collection of laboratory findings aside from HbA<sub>1c</sub>, it was not possible to fully assess the status of glycaemic and lipid control in the entire study population. Nevertheless, the relatively large numbers of patients with available laboratory results do allow for relative valid observations to be drawn.

### Conclusion

DaibCare 2012 has emphasized that still a large proportion of patients with T2DM in Bangladesh have unsatisfactory glycaemic and metabolic control, high prevalence of complications and suboptimal treatment adherence. The complexities and intricacies of providing quality diabetes care are challenging. Understanding the importance of comprehensive care and implementing the quality measures will help track progress and guide improvement. The study supports the current efforts of healthcare professionals towards diabetes care to bring down HbA<sub>1c</sub> <7% among Diabetics and demand aggressive strategies for high risk patients to prevent Diabetes. Improving awareness among health professionals and diabetic subjects with intensive education programs is also recommended.

### Acknowledgements

Authors acknowledge WorkSure India for providing medical writing assistance.

### Conflicts of interest

All authors declare no conflict of interests.

### References

1. International Diabetes Federation. IDF Diabetes eB, Belgium: International Diabetes Federation, 2015. <http://www.diabetesatlas.org>.
2. Engelgau MM, Narayan KM, Saaddine JB, Vinicor F. Addressing the burden of diabetes in the 21st century: better care and primary prevention. *Journal of the American Society of Nephrology* : JASN. 2003 Jul;14(7 Suppl 2):S88-91.
3. Cheema A, Adeloye D, Sidhu S, Sridhar D, Chan KY. Urbanization and prevalence of type 2 diabetes in Southern Asia: A systematic analysis. *Journal of global health*. 2014 Jun;4(1):010404.
4. Saquib N, Saquib J, Ahmed T, Khanam MA, Cullen MR. Cardiovascular diseases and type 2 diabetes in Bangladesh: a systematic review and meta-analysis of studies between 1995 and 2010. *BMC public health*. 2012;12:434.
5. Low WY LY, Samy AL. Non-communicable diseases in the Asia-Pacific region: Prevalence, risk factors and community-based prevention. *Int J Occup Med Environ Health* 2015;28:20-6.
6. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. *Diabetes care*. 1998 Sep;21(9):1414-31.
7. World health organization. Action plan for the prevention and control of noncommunicable diseases in South-East Asia -.
8. Attali JR. [DiabCare tools for the control of permanent improvement of the quality of care in diabetes]. *Diabete & metabolisme*. 1993 Dec;19(5 Suppl):533-7.
9. Raheja BS, Kapur A, Bhoraskar A, Sathe SR, Jorgensen LN, Moorthi SR, et al. DiabCare Asia—India Study: diabetes care in India—current status. *The Journal of the Association of Physicians of India*. 2001 Jul;49:717-22.
10. Latif ZA, Jain A, Rahman MM. Evaluation of management, control, complications and psychosocial aspects of diabetics in Bangladesh: DiabCare Bangladesh 2008. *Bangladesh Medical Research Council bulletin*. 2011 Apr;37(1):11-6.
11. Kibriya M, Mahtab H. Micro-Vascular complications in type-2 diabetes in Bangladesh: The diabcare-Asia, Bangladesh project. *Diabetes Research and Clinical Practice*. 2000;50:135-6.
12. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects. Seoul: 59th WMA General Assembly; 2008.
13. ISPE (International Society for Pharmacoepidemiology). Guidelines for good pharmacoepidemiology practices (GPP). 2007 April.
14. Standards of medical care in diabetes—2014. *Diabetes care*. 2014 Jan;37 Suppl 1:S14-80.
15. American Diabetes Association. Standards of medical care in diabetes-2014. . *Diabetes Care* 2014;37(Suppl 1): S14-S80.
16. Sultana Z, Ali ME, Akhtar MA, Uddin MS, Haque MM. A Study of Evaluation for the Management of Diabetes in Bangladesh. 2013.
17. Islam SM, Alam DS, Wahiduzzaman M, Niessen LW, Froeschl G, Ferrari U, et al. Clinical characteristics and complications of patients with type 2 diabetes attending an urban hospital in Bangladesh. *Diabetes & metabolic syndrome*. 2015 Jan-Mar;9(1):7-13.
18. Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. *Diabetes care*. 1993 Nov;16(11):1446-52.

19. Flynn MD, O'Brien IA, Corral R. The prevalence of autonomic and peripheral neuropathy in insulin-treated diabetic subjects. *Diabetic medicine : a journal of the British Diabetic Association*. 1995 Apr;12(4):310-3.
20. Ahmed Z, Hafez MA, Bari MA, Akhter J. Pattern of anti-diabetic drugs prescribed in a tertiary care hospital of Bangladesh. *International journal of basic and clinical pharmacology*. 2016 Jan-Feb;5(1):6-12.
21. Scheen AJ. Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes. *European journal of internal medicine*. 2012 Mar;23(2):126-31.
22. King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. *British journal of clinical pharmacology*. 1999 Nov;48(5):643-8.